Piggyback toric IOL effective for astigmatism

Article

Implanting a customized primary or a secondary piggyback toric IOL post-penetrating keratoplasty (PK) is effective for astigmatism, claims a paper in Eye.

Implanting a customized primary or a secondary piggyback toric IOL post-penetrating keratoplasty (PK) is effective for astigmatism, claims a paper in Eye.

Dr S. Srinivasan et al., Department of Ophthalmology, University Hospital Ayr, Ayr, Scotland, UK, conducted a prospective case series on nine eyes of nine patients with post-PK astigmatism.

Of the patients assessed, six underwent simultaneous phacoemulsification (PE) and three pseudophakic eyes received a secondary 'piggyback' toric IOL implanted in the ciliary sulcus. Outcome measures included Pre- and postoperative uncorrected (UDVA) and best-corrected (BDVA) distance visual acuities and refractive errors.

Change in magnitude of astigmatism pre- and postoperatively were calculated by Cartesian astigmatic vectors. Preoperative and postoperative endothelial cell counts were also assessed.

Preoperative UDVA improved from 1.13±0.51 logMAR to 0.48±0.24 postoperatively. BDVA findings did not present any significant changes from 0.31±0.27 to 0.26±0.19. Preoperative and postoperative refractive cylinder was 0.83±1.09 D and 3.89±4.01 D, respectively.

Astigmatic Cartesian x and y coordinates were significantly reduced and mean endothelial cell loss was 9.9%. Both implantation of a customized primary IOL or a secondary piggyback toric IOL were effective modalities for treating patients with high post-PK astigmatism.

To read the abstract please visit the journal here.

Recent Videos
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
John T. Thompson, MD, discusses his presentation at ASRS, Long-Term Results of Macular Hole Surgery With Long-Acting Gas Tamponade and Internal Limiting Membrane Peeling
ASRS 2024: Michael Singer, MD, shares 100-week results from the RESTORE trial
© 2024 MJH Life Sciences

All rights reserved.